Fluvoxamine
Fluvoxamine, Luvox (fluvoxamine) is a small molecule pharmaceutical. Fluvoxamine was first approved as Luvox on 1994-12-05. It is used to treat depressive disorder, obsessive-compulsive disorder, and panic disorder in the USA. The pharmaceutical is active against sodium-dependent serotonin transporter. In addition, it is known to target sigma non-opioid intracellular receptor 1.
Download report
Favorite
Events Timeline
Commercial
Clinical
Drug
Target
Variants
Financial
Trends
Safety
Events Timeline
5D
1M
3M
6M
YTD
1Y
2Y
5Y
Max
Events
FDA approval date
EMA approval date
Patent expiration date
Study first post date
Last update post date
Start date
Primary completion date
Completion date
Results first post date
Mock data
Subscribe for the real data
Subscribe for the real data
Commercial
Therapeutic Areas
Therapeutic Area | MeSH |
|---|---|
| mental disorders | D001523 |
Trade Name
FDA
EMA
Fluvoxamine, Luvox (discontinued: Fluvoxamine, Luvox)
Drug Products
FDA
EMA
New Drug Application (NDA)
New Drug Application (NDA)
Abbreviated New Drug Application (ANDA)
Abbreviated New Drug Application (ANDA)
Fluvoxamine maleate
Tradename | Company | Number | Date | Products |
|---|---|---|---|---|
| LUVOX | ANI Pharmaceuticals | N-021519 RX | 2007-12-20 | 3 products, RLD |
Show 2 discontinued
Labels
FDA
EMA
Brand Name | Status | Last Update |
|---|---|---|
| fluvoxamine maleate | ANDA | 2025-12-11 |
Indications
FDA
EMA
Agency Specific
FDA
EMA
No data
Patent Expiration
No data
HCPCS
No data
Clinical
Clinical Trials
102 clinical trials
View more details
Mock data
Subscribe for the real data
Subscribe for the real data
Indications Phases 4
Indication | MeSH | Ontology | ICD-10 | Ph 1 | Ph 2 | Ph 3 | Ph 4 | Other | Total |
|---|---|---|---|---|---|---|---|---|---|
| Depressive disorder | D003866 | EFO_1002014 | F32.A | — | 3 | — | 10 | 10 | 23 |
| Depression | D003863 | — | F33.9 | 1 | 1 | 1 | 7 | 12 | 22 |
| Obsessive-compulsive disorder | D009771 | EFO_0004242 | F42 | — | 1 | 3 | 8 | 7 | 19 |
| Compulsive personality disorder | D003193 | — | F60.5 | — | 1 | 2 | 8 | 7 | 18 |
| Major depressive disorder | D003865 | EFO_0003761 | F22 | — | 1 | — | 9 | 4 | 14 |
| Covid-19 | D000086382 | — | U07.1 | — | 4 | 7 | 1 | — | 12 |
| Anxiety disorders | D001008 | EFO_0006788 | F41.1 | — | — | 2 | 1 | 2 | 5 |
| Schizophrenia | D012559 | EFO_0000692 | F20 | — | — | 1 | 1 | 2 | 4 |
| Treatment-resistant depressive disorder | D061218 | — | — | — | — | — | 2 | 1 | 3 |
| Atrophy | D001284 | — | — | — | — | — | 1 | — | 1 |
Show 8 more
Indications Phases 3
Indication | MeSH | Ontology | ICD-10 | Ph 1 | Ph 2 | Ph 3 | Ph 4 | Other | Total |
|---|---|---|---|---|---|---|---|---|---|
| Severe acute respiratory syndrome | D045169 | EFO_0000694 | J12.81 | — | 1 | 2 | — | — | 3 |
| Post-acute covid-19 syndrome | D000094024 | — | — | — | 2 | 2 | — | — | 3 |
| Coronavirus | D017934 | — | — | — | 1 | 1 | — | — | 2 |
| Separation anxiety | D001010 | EFO_1001916 | — | — | — | 1 | — | 1 | 2 |
| Social phobia | D000072861 | EFO_1001917 | F40.1 | — | — | 1 | — | 1 | 2 |
| Generalized anxiety disorder | D000098647 | — | — | — | — | 1 | — | 1 | 2 |
| Severe acute respiratory syndrome-related coronavirus | D045473 | NCBITaxon_227859 | — | — | — | 1 | — | — | 1 |
| Dementia | D003704 | EFO_0003862 | F03 | — | — | 1 | — | — | 1 |
| Psychophysiologic disorders | D011602 | — | F45.9 | — | — | 1 | — | — | 1 |
| Somatoform disorders | D013001 | — | F45 | — | — | 1 | — | — | 1 |
Show 4 more
Indications Phases 2
Indication | MeSH | Ontology | ICD-10 | Ph 1 | Ph 2 | Ph 3 | Ph 4 | Other | Total |
|---|---|---|---|---|---|---|---|---|---|
| Coronavirus infections | D018352 | EFO_0007224 | B34.2 | — | 1 | — | — | — | 1 |
| Sars-cov-2 | D000086402 | — | — | — | 1 | — | — | — | 1 |
| Olfaction disorders | D000857 | — | R43.0 | — | 1 | — | — | — | 1 |
Indications Phases 1
Indication | MeSH | Ontology | ICD-10 | Ph 1 | Ph 2 | Ph 3 | Ph 4 | Other | Total |
|---|---|---|---|---|---|---|---|---|---|
| Healthy volunteers/patients | — | — | — | 16 | — | — | — | — | 16 |
| Drug interactions | D004347 | — | — | 2 | — | — | — | 1 | 3 |
| Neoplasms | D009369 | — | C80 | 2 | — | — | — | — | 2 |
| Breast neoplasms | D001943 | EFO_0003869 | C50 | 1 | — | — | — | — | 1 |
| Atopic dermatitis | D003876 | EFO_0000274 | L20 | 1 | — | — | — | — | 1 |
| Dermatitis | D003872 | — | L30.9 | 1 | — | — | — | — | 1 |
| Non-alcoholic fatty liver disease | D065626 | EFO_0003095 | K75.81 | 1 | — | — | — | — | 1 |
| Weight gain | D015430 | — | — | 1 | — | — | — | — | 1 |
| Fatty liver | D005234 | EFO_0003934 | — | 1 | — | — | — | — | 1 |
Indications Without Phase
Indication | MeSH | Ontology | ICD-10 | Ph 1 | Ph 2 | Ph 3 | Ph 4 | Other | Total |
|---|---|---|---|---|---|---|---|---|---|
| Taste disorders | D013651 | — | — | — | — | — | — | 3 | 3 |
| Cognitive dysfunction | D060825 | — | G31.84 | — | — | — | — | 2 | 2 |
| Drug-related side effects and adverse reactions | D064420 | — | T88.7 | — | — | — | — | 1 | 1 |
| Bipolar disorder | D001714 | EFO_0000289 | F30.9 | — | — | — | — | 1 | 1 |
| Wounds and injuries | D014947 | — | T14.8 | — | — | — | — | 1 | 1 |
| Pain | D010146 | EFO_0003843 | R52 | — | — | — | — | 1 | 1 |
| Substance-related disorders | D019966 | EFO_0003890 | F13 | — | — | — | — | 1 | 1 |
| Chronic disease | D002908 | — | — | — | — | — | — | 1 | 1 |
| Brain injuries | D001930 | — | S06.9 | — | — | — | — | 1 | 1 |
| Alcohol-related disorders | D019973 | — | F10 | — | — | — | — | 1 | 1 |
Show 14 more
Epidemiology
Epidemiological information for investigational and approved indications
View more details
Drug
General
| Drug common name | Fluvoxamine |
| INN | fluvoxamine |
| Description | Fluvoxamine is an oxime O-ether that is benzene substituted by a (1E)-N-(2-aminoethoxy)-5-methoxypentanimidoyl group at position 1 and a trifluoromethyl group at position 4. It is a selective serotonin reuptake inhibitor that is used for the treatment of obsessive-compulsive disorder. It has a role as an antidepressant, a serotonin uptake inhibitor and an anxiolytic drug. It is a 5-methoxyvalerophenone O-(2-aminoethyl)oxime and a member of (trifluoromethyl)benzenes. It is functionally related to a (trifluoromethyl)benzene. |
| Classification | Small molecule |
| Drug class | Selective serotonin reuptake inhibitor (SSRI) |
| Image (chem structure or protein) |  |
| Structure (InChI/SMILES or Protein Sequence) | COCCCC/C(=N\OCCN)c1ccc(C(F)(F)F)cc1 |
Identifiers
| PDB | — |
| CAS-ID | 54739-18-3 |
| RxCUI | — |
| ChEMBL ID | CHEMBL814 |
| ChEBI ID | 5138 |
| PubChem CID | 5324346 |
| DrugBank | DB00176 |
| UNII ID | O4L1XPO44W (ChemIDplus, GSRS) |
Target
Agency Approved
No data
Alternate
SIGMAR1
SIGMAR1
Organism
Homo sapiens
Gene name
SIGMAR1
Gene synonyms
OPRS1, SRBP
NCBI Gene ID
Protein name
sigma non-opioid intracellular receptor 1
Protein synonyms
Aging-associated gene 8 protein, hSigmaR1, SIG-1R, Sigma 1-type opioid receptor, Sigma1-receptor, Sigma1R, SR-BP, SR31747 binding protein 1, SR31747-binding protein
Uniprot ID
Mouse ortholog
Sigmar1 (18391)
sigma non-opioid intracellular receptor 1 (O55242)
Variants
No data
Financial
Revenue by drug
$
€
£
₣
Luvox – Jazz Pharmaceuticals
Mock data
Subscribe for the real data
Subscribe for the real data
Mock data
Subscribe for the real data
Subscribe for the real data
Tabular view
Estimated US medical usage
Fluvoxamine
Total medical expenditures per year (USD, in millions)
Mock data
Subscribe for the real data
Subscribe for the real data
Number of persons purchased
Mock data
Subscribe for the real data
Subscribe for the real data
Number of purchases
Mock data
Subscribe for the real data
Subscribe for the real data
Refill frequency
Mock data
Subscribe for the real data
Subscribe for the real data
Price per prescription (USD)
Mock data
Subscribe for the real data
Subscribe for the real data
Tabular view
Trends
PubMed Central
Top Terms for Disease or Syndrome:
Mock data
Subscribe for the real data
Subscribe for the real data
Additional graphs summarizing 10,978 documents
View more details
Safety
Black-box Warning
Black-box warning for: Fluvoxamine maleate
Adverse Events
Top Adverse Reactions
Mock data
Subscribe for the real data
Subscribe for the real data
4,007 adverse events reported
View more details
© 2020-2025 Collaborative Drug Discovery Inc. (CDD) | Terms of Use